<p>Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid</p>

Abstract

Introduction: Because tumor-associated inflammation is a hallmark of cancer treatment, in the present study, sorafenib mesoporous silica nanomatrix (MSNM@SFN) co-administrated with flufenamic acid (FFA, a non-steroidal anti-inflammatory drug (NSAID)) was investigated to enhance the anti-tumor activity of MSNM@SFN. Methods: Metastatic breast tumor 4T1/luc cells and hepatocellular carcinoma HepG2 cells were selected as cell models. The effects of FFA in vitro on cell migration, PGE2 secretion, and AKR1C1 and AKR1C3 levels in 4T1/luc and HepG2 cells were investigated. The in vivo anti-tumor activity of MSNM@SFN co-administrating with FFA (MSNM@SFN +FFA) was evaluated in a 4T1/luc metastatic tumor model, HepG2 tumor-bearing nude mice model, and HepG2 orthotopic tumor-bearing nude mice model, respectively. Results: The results indicated that FFA could markedly decrease cell migration, PGE2 secretion, and AKR1C1 and AKR1C3 levels in both 4T1/luc and HepG2 cells. The enhanced anti-tumor activity of MSNM@SFN+FFA compared with that of MSNM@SFN was confirmed in the 4T1/luc metastatic tumor model, HepG2 tumor-bearing nude mice model, and HepG2 orthotopic tumor-bearing nude mice model in vivo, respectively. Discussion: MSNM@SFN co-administrating with FFA (MSNM@SFN+FFA) developed in this study is an alternative strategy for improving the therapeutic efficacy of MSNM@SFN via co-administration with NSAIDs.

Antitumor Activity of the Zinc Oxide Nanoparticles Coated with Low-Molecular-Weight Heparin and Doxorubicin Complex In Vitro and In Vivo

“…The in vitro antitumor activity of ZnO-LD NPs was investigated in PC-3M and 4T1 cell lines using the SRB method, as previously reported. , Briefly, PC-3M cells and 4T1 cells were seeded in 96-well plates (8 × 10 3 cells/well) and incubated at 37 °C for 24 h. Then, cells were cultured with different concentrations of ZnO-LD NPs for 48 h. The cell viability was determined using SRB, which allowed quantification of the living cells by measuring absorbance at 540 nm by a 96-well plate reader (Elx808). The IC 50 values were calculated using dose–effect curves.…”

Screening for Potential Therapeutic Agents for Non-Small Cell Lung Cancer by Targeting Ferroptosis

“…Tumor-associated inflammation appears to be a new hallmark of cancer therapy ( Li Z.-Y. et al, 2020 ).…”

“…After the intersection of the two groups of screened drugs, we believed the small molecule compound, FFA, was a therapeutic agent to induce ferroptosis in NSCLC. Previous studies have found that FFA exerts antitumor effects (Matsumoto et al, 2016;Li Z.-Y. et al, 2020), suggesting that our screening strategy and results possess preferable credibility.…”

“…The formula to calculate cell viability was as follows: cell viability (%) = [A (treatment) − A (blank)]/[A (control) − A (blank)]. The cell wound healing assay was performed according to Li’s research ( Li Z.-Y. et al, 2020 ).…”

Fenamates as Potential Therapeutics for Neurodegenerative Disorders

“…Targeting neuroinflammation is a recent approach that has gained more attention due to the high failure rate of previous drug candidates [ 94 ]. The NLRP3 inflammasome is a well-known driver of tau pathology and there are several proven direct and indirect inhibitors of the NLRP3 inflammasome that have been identified [ 48 , 95 , 96 ]. However, inhibition of VRAC by MFA is a novel approach to NLRP3 inhibition, and researchers have suggested that it is important to consider indirect therapeutic methods as targeting the inflammasome itself may result in peripheral complications [ 97 ].…”